Where have all the graduate jobs gone — and will they come back?

The UK graduate jobs market is tightening sharply: the Institute of Student Employers reports an 8% drop in graduate roles year-on-year with a projected further 7% decline next year, while anecdotal hiring episodes show extreme oversubscription (eg. 3,500 applications for 16 trainee roles). Large recruiters have cut intakes (KPMG down ~29% last year; Deloitte scaled back 18% last year and is flat at 1,400; PwC reduced intake to 1,300 from 1,500 despite 47,000 applications) and firms such as Novo Nordisk have rescinded offers amid wider headcount culls. Employers and students cite generative AI as both reducing advertised entry-level vacancies (Adzuna data: ~45% fall since ChatGPT) and massively increasing low-quality, AI-produced applications, raising recruitment costs and signalling both sectoral labour disruption and downside risk to near-term economic activity.

Analysis

Market structure: The graduate market shows acute oversupply — ISE: -8% graduate jobs year-on-year and forecast -7% next year, while Adzuna reports entry-level ads down ~45% since ChatGPT and applications up ~40%. Immediate winners are training/apprenticeship providers, vocational-education vendors and enterprise AI infrastructure vendors that sell tools to automate screening; losers are large apprentice-hiring-dependent employers (big consultancies/accountancy pipelines) and firms with high cyclical junior intake like some pharma R&D/production teams.

Competitive dynamics & supply/demand: Excess applicant volume raises hiring processing costs, compresses starting wages for juniors and increases bargaining power of employers — expect longer hiring funnels and higher unit recruitment costs (measurable 10–30% rise in screening administrative expense for affected employers). In pharma, GLP-1 competition (Eli Lilly vs Novo Nordisk) creates near-term market-share swings that translate into discretionary hiring cuts and cancelled offers (NVO reported cuts), shifting pricing power in branded weight-loss/diabetes drugs.

Risk assessment & cross-asset impact: Short-term (days–months) recession signaling should push safe-haven demand: gilts and long-duration sovereigns bid, GBP likely underperform vs USD; corporate credit spreads for staffing/consumer cyclicals widen. Tail risks include rapid regulatory limits on AI hiring algorithms, surprise GLP-1 clinical/regulatory news, or an unexpected labour-market recovery; catalysts include quarterly hiring surveys, Big Tech AI spending announcements, and pharma sales releases over the next 3–6 months.

Contrarian & second-order views: Consensus underestimates that AI adoption remains operationally hard — hiring freezes are more cyclical than structural now, so deeply discounted staffing-tech or regional consultancies could rebound if GDP stabilises. Conversely, pharma incumbents with narrow GLP-1 moats (e.g., NVO) face real near-term execution risk; watch revenue guidance revisions and capex/hiring changes for early entry/exit signals.

Key Decisions for Investors

• Establish a tactical 1–1.5% portfolio short position in NVO via a 3-month put spread (buy 10% OTM, sell 20% OTM) to cap cost; thesis: 10–15% downside if GLP-1 market-share erosion and guidance cuts materialise. Exit/trim on a 15% adverse move or 12% realized downside.
• Implement a 2%/2% pair trade: long LLY (Eli Lilly) vs short NVO (Novo Nordisk) over 3–6 months, target 8–12% relative outperformance for LLY if Mounjaro demand continues to reallocate share; size to portfolio beta neutrality.
• Rotate portfolio: reduce cyclical domestic exposure (UK consumer discretionary and staffing/recruitment platforms) by 3–5% and redeploy into duration — buy 5Y and 10Y UK gilts equal to a 3% allocation as a hedge for recession risk; target a 20–40bp rally in yields within 3 months.
• Add a 1.5–2% long in AI infrastructure (e.g., NVDA) for 12–24 months as a structural play on enterprise AI adoption; hedge downside with a 6-month 7–10% OTM put to limit drawdown while capturing >20% upside potential on accelerating capex.